SamaCare publishes Q2 2026 benchmarks showing a 76.5% average net approval rate and 2.09‑day resolution time for medical benefit drug prior authorizations
Executive summary: SamaCare released its Q2 2026 Market Access Benchmarks for medical benefit drugs, reporting an average net approval rate of 76.5% and an average time to resolution of 2.09 days for prior authorizations conducted without manufacturer‑sponsored SamaCare intervention. These benchmarks offer transparent, comparable metrics that can inform payer‑provider negotiations, guide manufacturer market‑access tactics, and highlight variation by specialty, therapy stage, medication and payer workflow.
Who is involved: SamaCare (the healthcare technology firm that produced the analysis), along with the unspecified payers, providers and medication datasets underlying the prior‑authorization figures.
Likely next: Stakeholders are expected to cite these Q2 numbers in upcoming contracting and formulary discussions; SamaCare will likely continue its quarterly benchmark series with a Q3 2026 release.
The release provides a standardized view of prior‑authorization performance across specialties, therapy stages and payer workflows. By quantifying approval rates and turn‑around times without manufacturer‑sponsored support, the benchmarks give payers, providers and drug makers a common reference point for evaluating market‑access efficiency. The data highlight where bottlenecks exist and where process improvements could yield faster patient access.
Timeline
- — SamaCare Releases Q2 2026 Market Access Benchmarks for Medical Benefit Drugs (PR Newswire)
Analysis — what this means
Sectors affected
- Medical benefit drugs prior authorization market access
- Healthcare payer workflow optimization
- Pharmaceutical manufacturer market access strategy